18461820. MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)
Contents
- 1 MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
Organization Name
DANA-FARBER CANCER INSTITUTE, INC.
Inventor(s)
Levi A. Garraway of Newton MA (US)
Caroline Emery of Kansas City MO (US)
Nikhil Wagle of Brookline MA (US)
MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors - A simplified explanation of the abstract
This abstract first appeared for US patent application 18461820 titled 'MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
Simplified Explanation
The patent application discloses an isolated nucleic acid molecule encoding a mutant MEK1 protein with MEK1 activity. The mutant MEK1 protein has an amino acid substitution at position 121 of the wild-type MEK1, conferring resistance to RAF or MEK inhibitors on a cell expressing the mutant MEK1 protein.
- Mutant MEK1 protein with amino acid substitution at position 121 of wild-type MEK1
- Confers resistance to RAF or MEK inhibitors on expressing cells
Potential Applications
The mutant MEK1 protein could be used in cancer research to study resistance mechanisms to RAF or MEK inhibitors. It may also have applications in drug development for overcoming drug resistance in cancer treatment.
Problems Solved
The mutant MEK1 protein addresses the issue of drug resistance in cancer therapy by providing a potential target for developing new treatment strategies. It offers a way to study and understand the mechanisms of resistance to RAF or MEK inhibitors.
Benefits
The mutant MEK1 protein offers a novel approach to overcoming drug resistance in cancer treatment. It provides a tool for researchers to explore new therapeutic options and potentially improve patient outcomes.
Potential Commercial Applications
The technology could be licensed to pharmaceutical companies for drug development purposes. It may also have applications in personalized medicine for identifying patients who may benefit from alternative treatment strategies.
Possible Prior Art
One possible prior art could be studies on MEK1 mutations and drug resistance mechanisms in cancer cells. Research on RAF or MEK inhibitors and their effects on MEK1 signaling pathways could also be relevant prior art.
Unanswered Questions
== How does the mutant MEK1 protein specifically confer resistance to RAF or MEK inhibitors? The exact mechanism by which the amino acid substitution at position 121 of MEK1 confers resistance to RAF or MEK inhibitors is not clearly explained in the abstract. Further research may be needed to elucidate this mechanism.
== What are the potential off-target effects of using the mutant MEK1 protein in cancer therapy? The abstract does not mention any potential off-target effects of using the mutant MEK1 protein in cancer therapy. Additional studies may be required to assess the safety and efficacy of this approach in clinical settings.
Original Abstract Submitted
An isolated nucleic acid molecule encoding a mutant MEK1 protein having MEK1 activity is disclosed. The mutant MEK1 protein comprises an amino acid substitution at position 121 of wild-type MEK1 shown in SEQ ID NO: 2. The amino acid substitution confers resistance to one or more RAF or MEK inhibitors on a cell expressing the mutant MEK1 protein.
